Using light therapy to prevent hair loss from chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of photobiomodulation therapy (PBM) in preventing and managing chemotherapy-induced alopecia (CIA) in patients with gynecological and breast cancer. The research aims to determine if PBM can reduce the severity of hair loss associated with chemotherapy, thereby improving patients' quality of life. The therapy involves using a device that emits visible and near-infrared light to stimulate hair growth by enhancing blood flow to the scalp and promoting hair follicle metabolism. This approach is being compared to traditional scalp cooling methods, which have variable success rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with gynecological cancer (endometrium, cervix, ovarian or vulva) or breast cancer
* Receiving chemotherapy ((Carbo)-Taxol)
* Age ≥ 18 years
* Able to comply to the study protocol
* Able to sign written informed consent

Exclusion Criteria:

* Metastatic disease
* Pregnancy
* Active infection of the scalp
* Previous diagnosis of a hair loss condition
* Interruption of chemotherapy for more than two consecutive cycles
* Medication to stimulate hair growth (e.g., Minoxidil)
* Severe psychological disorder or dementia.
* Inability to speak and understand Dutch
* Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator
* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator

Where it's running

• Jessa Hospital
  Hasselt, Limburg, Belgium Recruiting

Study contacts

• Principal investigator: Jeroen Mebis, Prof. Dr. — Jessa Hospital
• Study coordinator: Jeroen Mebis, Prof. Dr.
• Email: jeroen.mebis@jessazh.be
• Phone: +32 11 33 72 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DA-020 topically for chemotherapy-induced hair loss

  This study tests DA-020 (a topical alpha-1 agonist) to see if it can reduce hair loss in people with breast cancer receiving certain chemotherapies.

  Recruiting Phase 1/2 Applied Biology, Inc. · Manaus and 1 other locations · NCT07397325

• Testing the Lily Device for reducing hair loss during chemotherapy

  This study is testing the Lily Device to see if it can help women with breast cancer keep their hair during chemotherapy.

  Recruiting at 5 sites Luminate Medical, Inc. · Mullica Hill, New Jersey and 4 other locations · NCT06786078

• Portable scalp cooling system to prevent hair loss during chemotherapy

  This study is testing if a portable cooling device can help women with early-stage breast cancer keep their hair while undergoing chemotherapy.

  Recruiting at 2 sites Cooler Heads Care Inc. · Tucson, Arizona and 1 other locations · NCT05484973

• Using scalp cooling to prevent hair loss in metastatic breast cancer patients

  This study is testing if using a scalp cooling system during chemotherapy can help prevent hair loss in people with metastatic breast cancer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04986579

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.